期刊文献+

华法林合用盐酸左氧氟沙星致全身出血1例 被引量:2

下载PDF
导出
摘要 1临床资料 患者女性,64岁,主因“尿频、尿急、尿痛2 d,发热1d”入院。既往有持续性心房纤颤(房颤)病史5年,长期口服华法林2.5 mg,1/日,每月复查血凝四项,入院前1月未复查血凝四项,无出血迹象,无高血压及糖尿病病史。入院前2d患者出现尿频、尿痛、尿急症状,尿混浊,无肉眼血尿和脓性尿,入院前1 d发热,体温最高38.8℃,未做抗感染治疗。查体:腹软,下腹轻压痛,无反跳痛,肠鸣音正常,无其它阳性体征。在门诊尿常规可见白细胞满视野,无红细胞;泌尿系彩超未见异常。自发病以来,精神不振,食欲减退,进食少,无腹痛,未述其它不适。入院诊断:急性泌尿系感染。给予盐酸左氧氟沙星注射液0.2 g静点,输液后4 h,患者诉头痛、恶心,左侧上下肢麻木无力,双眼视物模糊,咳嗽、咯血、腹痛、黑便、肉眼血尿,查体可见全身皮肤广泛出血点和瘀斑,双侧眼球结膜出血,颈软,心肺听诊未见异常,腹软,全腹轻压痛,无肌紧张,肠鸣音活跃,左侧上下肢肌力3级,肌张力减弱,左侧Babinski征阳性,右侧上下肢肌力、肌张力正常,病理征阴性。考虑华法林相关性凝血机制障碍性出血,立即肌注维生素K110 mg[1,2],急查血凝四项,INR为9.5,凝血时间和部分凝血酶原时间均明显延长,凝血酶原时间26 s,凝血酶时间32 s,纤维蛋白原3 g/L。做头颅CT显示右侧基底节区出血,眼底检查可见双眼眼底出血,粪便潜血试验(+),尿常规可见红细胞满视野。停盐酸左氧氟沙星注射液,继续给患者口服维生素K4片,4 mg,3/日,每日2次监测INR,直至3 d后INR降到3以下,停维生素K4片,患者尿血、便血、咯血停止,视力恢复接近正常,左侧上下肢肌力恢复基本正常。
机构地区 解放军第
出处 《中国循证心血管医学杂志》 2015年第3期411-411,共1页 Chinese Journal of Evidence-Based Cardiovascular Medicine
  • 相关文献

参考文献6

二级参考文献38

  • 1孟旭,李金钟,刘岩,张海波.人工机械瓣膜置换术后口服抗凝药的抗凝治疗强度标准[J].中华心血管病杂志,2004,32(7):618-621. 被引量:58
  • 2方圻,王思让.心律失常的临床对策[J].中华心血管病杂志,1993,21(1):5-14. 被引量:39
  • 3Zubhov A,Claassen DO,Rabinstein AA.Warfarin associated intraventricular hemorrhage[J].Neurol Res,2007,29(7):661-663.
  • 4Davis SM,Broderick J,Hennerici M,et al.Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage[J].Neurology,2006,66(8):1175-1181.
  • 5Radberg JA,Olsson JE,Radberg CT.Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment[J].Stroke,1991,22(5):571-576.
  • 6Aguilar MI,Hart RG,Kase CS,et al.Treatment of warfarin associated intracerebral hemorrhage:literature review and expert opinion[J].Mayo Clin Procm,2007,82(1):82-92.
  • 7Lankiewicz MW,Hays J,Friedman KD,et al.Urgent reversal of warfarin with prothrombin complex concentrate[J].J Thromb Haemost,2006,4(5):967-970.
  • 8Yasaka M,Sakata T,Minematsu K,et al.Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication[J].Thromb Res,2002,108(1):25-30.
  • 9Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation : the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010,31:2369.
  • 10Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest, 2010,137:263.

共引文献801

同被引文献28

  • 1黄从新,马长生,杨延宗,黄德嘉,张澍,江洪,杨新春,吴书林,马坚,刘少稳,李莉,曹克将,王方正,陈新.心房颤动:目前的认识和治疗建议(二)[J].中华心律失常学杂志,2006,10(3):167-197. 被引量:269
  • 2郑策,梅丹.影响华法林抗凝血作用的有关因素[J].药物不良反应杂志,2007,9(4):256-261. 被引量:102
  • 3Taylor J. Cardio Pulse. A focused update to the ESCguidelines for the management of patients with atrial fi-brillation[J].Eur Heart J, 2012,33(21) :2623-2624.
  • 4Banet G A, Waterman A D, Miligan P E, ei al. Warfarindose reduction vs watchful waiting for mild elevations inthe international normalized ratio [ J]. Chest,2003 , 123(2):499-503.
  • 5Xiong Q, Lip G Y. Selection of warfarin or one of thenew oral antithrombotic agents for long-term prevention ofstroke among persons with atrial fibrillation [ J ]. CurrTreat Options Neurol, 2015 ,17(2) :331.
  • 6Lewalter T, Ibrahim R, Albers B, et al. An update andcurrent expert opinions on percutaneous left atrial append-age occlusion for stroke prevention inatrial fibrillation[J].Europace, 2013,15(5) :652-656.
  • 7Reddy V Y, Mobius Winkler S, Miller M A, ei al. Leftatrial appendage closure with the Watchman device in pa-tients with a contraindication for oralanticoagulation : theASAP study ( ASA Plavix Feasibility Study With Watch-man Left Atrial Appendage ClosureTechnology) [ J]. J AmColl Cardiol, 2013,61(25) :2551-2556.
  • 8Holmes D R,Reddy V Y, Turi Z G, et al. Percutaneousclosure of the left atrial appendage versus warfarin therapyfor prevention of stroke in patients withatrial fibrillation : arandomised non-inferiority trial [ J ]. Lancet, 2009 , 374(9689) :534-542.
  • 9Amorosi S L, Armstrong S, Da Deppo L, et al. Thebudget impact of left atrial appendage closure comparedwith adjusted-dose warfarin and dabigatran etexilateforstroke prevention in atrial fibrillation [ J ]. Europace,2014,16(8) :1131-1136.
  • 10Camm A J, Lip G Y, De Caterina R, et al. 2012 focusedupdate of the ESC Guidelines for the management of atrialfibrillation : anupdate of the 2010 ESC Guidelines for themanagement of atrial fibrillation—developed with the spe-cial contribution of the European Heart Rhythm Associa-tion[J].Europace, 2012,14(10) :1385-1413.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部